A Phase 1, Randomized, Double-blind, Placebo-controlled, Single-Ascending-Dose Trial to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of Intravenous PNT001 in Healthy Volunteers
Latest Information Update: 04 Nov 2021
At a glance
- Drugs PNT 001 (Primary)
- Indications Neurodegenerative disorders
- Focus Adverse reactions; First in man
- Sponsors Pinteon Therapeutics
Most Recent Events
- 19 Feb 2021 Status changed from active, no longer recruiting to completed.
- 01 Feb 2021 Results published in the Pinteon Therapeutics Media Release
- 28 Jan 2021 According to a Pinteon Therapeutics media release, data from this trial will be presented at the 15th International Conference on Alzheimer's and Parkinson's Diseases (AD/PD 2021).